Ellen Chiniara - Jan 3, 2023 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role: Chief Legal Officer
Signature: /s/ Bruce Jacobs, as Attorney-in-Fact
Stock symbol: KYMR
Transactions as of: Jan 3, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/4/2023, 03:35 PM
Previous filing: Apr 28, 2022
Next filing: Feb 9, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYMR	Common Stock	Award	$0	+37.5K		$0.00	37.5K	Jan 3, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYMR	Stock Option (Right to Buy)	Award	$0	+225K		$0.00	225K	Jan 3, 2023	Common Stock	225K	$24.84	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following January 3, 2023, subject to the reporting person's continued employment through each vesting date.
F2	25% of the shares underlying this stock option shall vest on January 3, 2024, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.